A multicenter, global, phase II study is currently under way that is evaluating the safety and efficacy of zanidatamab in combination with standard chemotherapy in patients with HER2-positive gastrointestinal cancer, including CRC (NCT03929666). The gene discussed is ERBB2; the disease is colorectal carcinoma.